Company intelligence / Profile preview
Phoenix Molecular Designs
Vancouver, British Columbia, Canadaphoenixmd.ca ↗
- Ownership
- Private
- Employees
- ~19
- Development stage
- Phase 2
01
Overview
Phoenix Molecular Designs has advanced its lead compound, PMD‑026—a first-in-class small molecule inhibitor targeting the RSK pathway—into Phase 2 clinical trials for breast cancer. The company’s approach addresses resistance to current therapies and aims to improve outcomes in difficult-to-treat cancers such as TNBC. No published late-stage or commercial results yet.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule kinase inhibitors
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Phoenix Molecular Designs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phoenix Molecular Designs.